CJC-1295

CJC-1295 is a synthetic peptide that stimulates your pituitary gland to produce growth hormone. What makes it special is its extended duration — while natural growth hormone-releasing hormone lasts only minutes, CJC-1295 can keep working for up to two weeks. **How does it work?** CJC-1295 uses "Drug Affinity Complex" (DAC) technology — essentially, it attaches to albumin (a protein in your blood), which dramatically extends how long it stays active in your body. This means sustained, steady growth hormone elevation rather than quick spikes. **What the research shows:** • Increases growth hormone levels in a more natural, pulsatile pattern • May support lean muscle growth and fat metabolism • Could improve recovery and sleep quality • Often combined with Ipamorelin for synergistic effects **CJC-1295 vs. Mod GRF 1-29:** You might see "CJC-1295 without DAC" or "Mod GRF 1-29" — this is a shorter-acting version requiring more frequent dosing but offering more control over GH pulses. **Typical use:** Injected subcutaneously, usually 1-2 times per week for the DAC version, or 2-3 times daily for the non-DAC version. **Important to know:** CJC-1295 is banned by WADA and not FDA-approved for any medical condition. Human clinical data remains limited. --- **Sources:** Teichman SL, et al. (2006) Journal of Clinical Endocrinology & Metabolism | Journal of Pharmaceutical and Biomedical Analysis (2022). DOI:10.1016/j.jpba.2022.114726

Human data are limited to small, short-term, single-center healthy-volunteer studies from the early 2000s; no phase 3 trials or approvals followed. Effects on body composition, recovery, or aging outcomes have not been clinically validated. The peptide is widely sold for research/off-label use without regulatory oversight, and long-term safety is unknown.

CJC-1295 is a GHRH analog with a DAC moiety that binds endogenous albumin after injection, giving an estimated elimination half-life of 5.8-8.1 days (albumin-tethered form). Subcutaneous administration of single doses 30-150 mcg/kg raised GH and IGF-1 dose-dependently; pulsatile GH secretion was preserved. A separate non-DAC 'modified GRF 1-29' product has a much shorter half-life and is a distinct compound.